CTOs on the Move

www.mycomedica.bio

www.mycomedica.bio

 
Co-Founded by world-renowned mycologist Paul Stamets, MycoMedica, PBC is a life sciences company developing therapeutic drugs derived from fungi to help people live healthier, better lives.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

www.mycomedica.bio raised $60M on 06/01/2022

Similar Companies

Artemisia BioMedical

Artemisia BioMedical is a Renton, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FEI Systems

FEI Systems is a leading IT company specializing in Federal and Local Government data system solutions, and for the past decade we have maintained a leading position in providing programming and consulting services in our primary areas of expertise- Behavioral Health Data Systems, and Clinical Trials Software Solutions for institutional systems of care. At the heart of our success you`ll find a talented team of experts who have helped our customers bridge the gap between the business needs of their organization, and the application of technologies required to successfully manage them.

Enveda Biosciences

At Enveda, we are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. Our platform harnesses nature`s complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics.

Calithera

Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

Family Dental

Family Dental is a Haverhill, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.